1 2 n o v e m b e r 2 0 1 5 | v o L 5 2 7 | n A T U r e | 2 4 9 Epigenetic silencing including histone modifications and DNA methylation is an important tumorigenic mechanism 1 . However, its role in cancer immunopathology and immunotherapy is poorly understood. Using human ovarian cancers as our model, here we show that enhancer of zeste homologue 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1
reduced tumour volume, increased tumourinfiltrating CD8 + T cells and T H 1type chemokine expression (Extended Data Fig. 1g -i). Thus, changes in the epigenetic program can augment the therapeutic efficacy of PDL1 blockade therapy.
In the third setting, we examined the effects of these two epige netic modulators on adoptive Tcell therapy in our NSG model. We established human ovarian cancer in NSG mice and generated tumourassociated antigen (TAA)specific CD8 + T cells [12] [13] [14] . Then, the NSG mice were treated with DZNep and 5AZAdC, and/or TAA specific CD8 + T cells. In the absence of TAAspecific T cells, treatment with DZNep and 5AZAdC had minimal effects on tumour progres sion. TAAspecific CD8 + T cells reduced tumour volume (Extended Data Fig. 1j ). Consequently, treatment with DZNep and 5AZAdC improved the therapeutic efficacy of Tcell therapy, and elevated T H 1 type chemokine expression, and tumour effector Tcell infiltration (Extended Data Fig. 1j-l) . GSK126 is a selective inhibitor of EZH2 methyltransferase activity 15 . We used GSK126 in the human Tcell ther apy setting. Treatment with low doses of GSK126 and/or 5AZAdC had no effect on tumour growth in the absence of Tcell transfusion (Extended Data Fig. 1m ). Treatment with GSK126 and 5AZAdC syn ergistically improved the therapeutic efficacy of Tcell therapy ( Fig. 1a and Extended Data Fig. 1m ), increased tumour CXCL9 and CXCL10 expression ( Fig. 1b, c) , and CD8 + Tcell infiltration (Fig. 1d , e and Extended Data Fig. 1n ), and had minimal effects on TNFα and IFNγ expression (Extended Data Fig. 1o -q). Administration of antihuman CXCR3 abrogated the role of GSK126 and 5AZAdC treatment in tumour progression (Fig. 1a ), and blocked Tcell tumour trafficking ( Fig. 1d, e ), and had no effect on Tcell apoptosis (Extended Data Fig. 1r , s). CXCR3 + CD8 + T cells were observed in the spleen (Extended Data Fig. 1t ) and blood ( Fig. 1e ) with or without antiCXCR3 treat ment. To determine the major source of T H 1type chemokines, we isolated human tumour and immune cells from tumour tissues in the NSG mice ( Fig. 1a-e ). We found that administration of GSK126 and 5AZAdC increased tumour CXCL10 expression with or with out Tcell transfusion ( Fig. 1f ). Regardless of the treatment, the lev els of CXCL10 expression were higher in tumour than immune cells ( Fig. 1f) . We extended our studies to tumour and immune cells from ovarian cancer patients. Although EZH2 may regulate naive CD4 + Tcell interferonγ (IFNγ ) expression 16 , GSK126 and 5AZAdC treat ment increased CXCL10 production by tumour, not by T cells (Fig. 1g ), and tumour cells produced higher levels of CXCL10 than immune cells ( Fig. 1g) . Thus, epigenetic reprograming may predominantly target tumour T H 1type chemokine expression.
Next, we investigated how epigenetic modulators regulate tumour T H 1type chemokine expression. We initially examined the effect of DZNep on T H 1type chemokine expression in primary human ovarian Letter reSeArCH © 2015 Macmillan Publishers Limited. All rights reserved cancer cells in response to IFNγ treatment. DZNep promoted CXCL9 and CXCL10 mRNA and protein expression (Extended Data Fig. 2a-c) , and had no effect on IFNγ receptor (IFNGR2) (Extended Data Fig. 2d ). We tested two inhibitors of histone H3 lysine 9 methyltransferase G9a, BIX01294 and UNC0638. The inhibition of G9a had no effect on T H 1 type chemokine expression (Extended Data Fig. 2e ). Thus, methylation of H3K27 may mediate T H 1type chemokine repression in cancer.
EZH2 is the catalytic subunit of the H3K27 methyltransferase complex 9, 17 . DZNep treatment reduced EZH2 protein expression and H3K27 trimethylation (H3K27me3) in primary ovarian cancer cells (Extended Data Fig. 2f ). Similarly, EPZ6438 reduced H3K27 trimethylation and increased CXCL9 expression in mouse ID8 cells (Extended Data Fig. 2g , h). We genetically knocked down human EZH2 expression with lentivirusbased short hairpin RNA targeting EZH2 (shEZH2). shEZH2 reduced the expression of EZH2 and H3K27me3 (Extended Data Fig. 2i ), and resulted in elevated T H 1type chemokine mRNA and protein expression ( Fig. 2a, b ), and no change in IFNGR2 and HLAB (Extended Data Fig. 2j , k). Thus, EZH2 and its histone methyltransferase activity mediate T H 1type chemokine repression in primary ovarian cancer cells.
We tested whether EZH2mediated T H 1type chemokine repression depends on H3K27me3 changes at the promoter level. Chromatin immu noprecipitation (ChIP) assays revealed that IFNγ treatment reduced H3K27me3 levels on the promoters of CXCL9 and CXCL10 (Extended Data Fig. 2l , m). DZNep (Extended Data Fig. 2l , m) and shEZH2 ( Fig. 2c ) largely removed H3K27me3 on the promoters of CXCL9 and CXCL10, and subsequently increased IFNγ induced chemokine gene expression ( Fig. 2a, b ). As a positive control, shEZH2 reduced H3K27me3 occupancy on the promoter of the HoXb1 gene (Extended Data Fig. 2n ) 18 . Thus, H3K27me3 removal results in the abrogation of the T H 1type chemokine gene silencing in primary ovarian cancer.
GSK126 is a selective inhibitor of EZH2 methyltransferase activ ity 15 . GSK126 treatment abolished the global level of H3K27me3 with out inhibiting EZH2 (Extended Data Fig. 3a, b) , IFNGR2 expression or cell survival (Extended Data Fig. 3c, d ). GSK126 treatment led to higher levels of IFNγ induced T H 1type chemokine expression in two primary and three established ovarian cancer cell lines ( Fig. 2d and Extended Data Fig. 3e -h). JmjCdomaincontaining protein (JMJD3) is an H3K27specific demethylase 18 . Ectopic expression of JMJD3 reduced H3K27me3 (Extended Data Fig. 3i ), increased T H 1type chemokine expression ( Fig. 2e and Extended Data Fig. 3j ), and had no effect on HLA-b and IFNGR2 expression (Extended Data Fig. 3k , l). JMJD3 deficiency introduced by a shJMJD3 inhibited CXCL10 (Fig. 2f ), but not IFNGR2 expression (Extended Data Fig. 3m ).
GSKJ4, a catalytic site inhibitor, may target members of the H3K27 specific JmjC demethylase subfamily 19 . GSKJ4 treatment increased H3K27me3 (Extended Data Fig. 3n ) and reduced CXCL9 and CXCL10 expression ( Fig. 2g ), and had no effects on H3K4me1, H3K4me2 or H3K4me3 or IFNGR2 expression (Extended Data Fig. 3n , o).
To define the gene profile altered by EZH2 and H3K27me3 in response to IFNγ , we performed several microarrays in primary ovarian cancer cells transfected with shEZH2, control, or treated with GSK126 and medium. We found that 155 and 124 genes were altered by shEZH2 and GSK126 treatment, respectively, and the expression of 20 genes was increased or decreased by both shEZH2 and GSK126 treatment. CXCL9 and CXCL10 were at the top 1 and 3 positions among the increased genes in the arrays (Fig. 2h ). Altogether, the data indicate that H3K27me3 specific methyltransferase and demethylase preferentially and predominantly regulate T H 1type chemokine repres sion in primary ovarian cancer cells.
DNA methylation regulates gene expression through DNA methyltransferases (DNMTs). We treated two primary and one established ovarian cancer cell line with 5AZAdC. 5AZAdC treat ment increased CXCL9 and CXCL10 mRNA and protein expression ( Fig. 3a -c and Extended Data Fig. 4a-d ). IRF1 and IFNGR2 were not affected by 5AZAdC treatment (Extended Data Fig. 4e , f). Specific knockdown of DNMT1 (Extended Data Fig. 4g ) increased CXCL9 and CXCL10 mRNA and protein expression ( Fig. 3d-f ), but had no effect on IFNGR2 (Extended Data Fig. 4h ). To demonstrate DNA methyl ation status in the CXCL10 locus, we carried out bisulfite genomic sequencing on the CXCL10 gene locus and analysed the methylation at the CXCL10 gene loci containing the STAT1binding site ( Fig. 3g and shown. SSC, side scatter; hCD8, human CD8 + T cell. f, CXCL10 transcripts were quantified in tumour and immune cells from tumour tissues in NSG model and normalized to GAPDH mRNA level. g, Tumour and immune cells (1 × 10 6 per ml) were isolated from ovarian cancer from patients, and were treated for 48 h as indicated. CXCL10 protein was measured by ELISA (mean ± s.d., n = 5, * P < 0.05, Mann-Whitney Utest). Extended Data Fig. 4i ). The genomic location of bisulfite sequenc ing was 5′ upstream of the CXCL10 promoter (−5 kb to −4.7 kb). 5AZAdC treatment reduced DNA methylation of the CXCL10 gene locus ( Fig. 3g ). Thus, DNA methylation regulates T H 1type chemokine expression. We examined the relationship between EZH2/H3K27me3 and DNA methylation in the regulation of chemokine expression. We treated primary ovarian cancer cells with 5AZAdC or GSK126, and found that 5AZAdC reduced DNMT1 expression but had no effect on H3K27me3 or H3K9me2, whereas GSK126 reduced H3K27me3 but had no effect on DNMT1 expression ( Fig. 4a ). Thus, DNA methylation and EZH2/H3K27me3 histone modification may not reciprocally regu late at the protein level in primary ovarian cancer. We explored whether EZH2/H3K27me3 and DNA methylation could independently mediate T H 1type chemokine repression. We examined the effects of 5AZAdC on shEZH2 cells, and observed that 5AZAdC enhanced 
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Control vs. GSK126 CXCL10 expression ( Fig. 4b ). Similarly, GSK126 increased CXCL10 expression in shDNMT1 cells ( Fig. 4c ). Primary ovarian cancer cells released higher levels of CXCL10 in the combinatorial treatment of DZNep and 5AZAdC compared to either treatment alone ( Fig. 4d ). These data suggest that H3K27me3 and DNA methylation can inde pendently repress tumour T H 1type chemokine expression.
We studied the interaction between EZH2 and DNMT1 in the ovar ian cancer microenvironment and its clinical relevance (Extended Data Table 1 ). We quantified the nuclear levels of EZH2 and DNMT1 (Extended Data Fig. 5a , b) via immunohistochemistry in human ovarian cancer tissues by the Hscore method 11 and analysed their impact on patient survival (Extended Data Table 1 ). Based on the median values of EZH2 and DNMT1 intensity, we divided patients into 'low' and 'high' groups. Overall survival and disease freeinterval (DFI) (Extended Data Table 1) were shorter in patients with high levels of EZH2 ( Fig. 4e and Extended Data Fig. 5c ) and DNMT1 ( Fig. 4f and Extended Data Fig. 5d ), compared to patients with low levels of these markers. After adjusting for the prognostic clinical fac tors, overall survival and DFI remained shorter in patients with high EZH2 and DNMT1 expression (Extended Data Table 2 ). Tumour EZH2 and DNMT1 were positive predictors of risk of death in univariate (Extended Data Table 1 ) and multivariate analyses (Extended Data Table 2 ). The reduced overall survival and DFI were more pronounced in the combination of high levels of EZH2 and DNMT1 than EZH2 or DNMT1 alone (Extended Data Table 3 ).
To estimate the performance of EZH2 and DNMT1 on predicting survival, we used the timedependent receiver operating characteristic (ROC) curve analysis 20 . The area under the ROC curve (AUC) is calcu lated to evaluate the predictive accuracy of each marker for estimating survival. The analysis revealed similar AUCs for EZH2 and DNMT1 in predicting overall survival and DFI (Fig. 4g , Extended Data Fig. 5e and Extended Data Table 4 ). The expression of EZH2 and DNMT1 may be equally important in ovarian cancer pathology. Next, we eval uated significance of the two parameters for ovarian cancer survival. Given the negative and independent impact of EZH2 and DNMT1, we reasoned that both parameters are more efficient at predicting sur vival than individually. Indeed, EZH2 high DNMT1 high patients experi enced a shorter overall survival and DFI (Extended Data Table 3) than EZH2 low DNMT1 low patients in univariate and multivariate analysis (Fig. 4h ). Patients with mixed patterns had similar and moderate sur vival ( Fig. 4h and Extended Data Fig. 5f ). Thus, the combination of EZH2 and DNMT1 allows for improved prognostic stratification of ovarian cancer survival as compared to EZH2 or DNMT1 alone. Next, we quantified intratumoural CD8 + T cells by immunohistochemistry (Extended Data Fig. 5g ), and found that there was a correlation between tumour CD8 + Tcell content and survival (Extended Data Tables 1 and 2). We divided the patients into two groups based on the median values of CD8 + Tcell number. Patients with more CD8 + T cells experienced longer overall survival and DFI scores compared to those with fewer CD8 + T cells 21, 22 (Fig. 4i and Extended Data Fig. 5h ). ROC curve analy sis revealed similar power of CD8 + T cells in predicting overall survival ( Fig. 4g ) and DFI (Extended Data Fig. 5e ).
Finally, we observed that the levels of EZH2 (Fig. 4j ) and DNMT1 (Fig. 4k ) were inversely associated with CD8 + T cells. The accumulating analysis was applied to evaluate the predictive accuracy of each marker for overall survival (t = 60 months). h, Impact of EZH2 and DNMT1 on overall survival. EZH2 low DNMT1 low (n = 50), EZH2 high DNMT1 high (n = 57), EZH2 low DNMT1 high (n = 32), and EZH2 high DNMT1 low (n = 66) were compared. Logrank test, P < 0.0001, EZH2 low DNMT1 low versus EZH2 high DNMT1 high . i, The relationship between intratumoural CD8 + T cells and overall survival; P < 0.0001. j-l, The Pearson correlation between intratumoural CD8 + T cells and EZH2 (n = 169, r = − 0.24, P = 0.002) (j) and DNMT1 (n = 170, r = − 0.28, P = 0.0003) (k) and the accumulating levels of EZH2 and DNMT1 (n = 168, r = − 0.32, P < 0.0001) (l). Gene expression levels are represented as relative values normalized to GAPDH mRNA level. I   I I I  I I I I  I I I I  I I  I I   I I   I I   I  I   I   I I  I   I I I I I  I I   I I I I I I I I   I I I I   I I I  I  I  I levels of EZH2 and DNMT1 negatively correlated with the number of intratumoural CD8 + T cells (Fig. 4l) . Altogether, the results suggest that tumours coopt certain epigenetic pathways, silence T H 1type chemok ine expression and repress Tcell tumour homing, which functions as a novel immuneevasion mechanism.
To maintain cellular identity, through epigenetic mechanisms, key 'stemness' genes may be repressed in somatic cells, and key effector genes may be silenced in stem cells 23, 24 . Tumour cells may gain stem cell properties 11 . This may explain why T H 1type chemokines, as effector genes, are repressed in cancer. Epigenetic silencing is an intrinsic tum origenic mechanism 1 . We propose a unifying model of cancer in which epigenetic dysregulation has dual biological and immunological roles in supporting tumour progression. Cancer immunotherapies 4, 5, 7, 8, 25 and classic therapies [26] [27] [28] rely on efficient Tcell tumour trafficking, and may induce and/or expand mutated TAAspecific T cells 29, 30 . Applicably, our work suggests that epigenetic reprograming may condition tumours from poor Tcell infiltration to rich Tcell infiltration 6 , and ultimately potentiate cancer therapy (Extended Data Fig. 5i ).
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Ovarian cancer patients, cancer tissue samples and primary ovarian cancer cells.
Patients diagnosed with highgrade serous ovarian carcinomas were recruited for this study. Human subject use in this study was approved by the local Institutional Review Boards and informed consent was obtained from the patients. We collected 186 formalinfixed, paraffinembedded ovarian tumour tissue blocks (Extended Data Table 1 ) and 20 fresh ovarian cancer tissues for this study as described previously 2, 12, 31 . After pathological review, a tissue microar ray (TMA) 11, 32 was constructed from the most representative area of paraffin embedded ovarian tumour tissue. For each tumour, a minimum of two represent ative tumour areas were selected from a haematoxylin and eosinstained section of a donor block. Core cylinders (1 mm) were punched from each of these areas and deposited into a recipient paraffin block. Consecutive 6μ mthick TMA sections were cut and placed on charged polyllysinecoated slides for immunohistochem istry analyses. Epithelial cell adhesion moleculeexpressing (EpCAM + ) primary tumour cells, CD3 + CD45 + T cells, and CD45 + immune cells were isolated and sorted from fresh ovarian cancer tissues for functional studies. Primary human ovarian cancer cell lines (OC8 and OC17) were generated from fresh ovarian can cer tissues and/or ascites fluid in our laboratory as previously described 11, 13, 33 . Three commercialized ovarian cancer cell lines A2780, CAOV3 and ES2 were included in the study. The cell lines were routinely tested for mycoplasma con tamination. All the commercialized cell lines were authenticated by the supplier and used within ten passages. Primary ovarian cancer cells were authenticated in the laboratory. Plasmids, shRNA and antibodies. pCMVHAJMJD3 plasmid was obtained from Addgene (#24167). Lentiviral shRNAs (Extended Data Table 5) Table 5 .
Gene expression microarray was carried out at the University of Michigan Microarray Core Facility using Affymetrix Human Gene ST 2.1 Chip accord ing to the standard protocol. Data was analysed by the University of Michigan Bioinformatics Core Facility. Two biological replicates of each sample were pre pared independently from primary human ovarian cancer cells for gene expression profiling. Genes with > 1.5fold changes were selected for further analysis. Chromatin immunoprecipitation (ChIP). ChIP assay was performed as described previously 11, 32 . Sonication was performed with the Misonix 4000 water bath sonication unit at 15% amplitude for 10 min. ChIPenriched chromatin was analysed by realtime PCR with SYBR Green Master Mix, and normalized to the input. The ChIP primers were listed in the Extended Data Table 5 .
Immunofluorescence staining (IF) and immunohistochemistry staining (IHC).
Mouse tumour xenografts were harvested and either fixed in 10% buffered for malin and embedded in paraffin for immunohistochemistry assay, or immediately frozen and embedded in OCT compound embedding medium for immunoflu orescence staining. The immunofluorescence staining was performed with the monoclonal antiCD8 (HIT8a, #550372, BD Biosciences). Alexa Fluor 488 or Alexa Fluor 563 conjugated antimouse secondary antibodies (Life Technologies) were used. Staining with isotype antibody was used as negative control. T cells were counted manually at 10-20 highpower fields under a fluorescence microscope (Leica). Immunohistochemical staining on human TMA slides or frozen ovar ian cancer tissue sections was performed on a DAKO autostainer (DAKO) using DAKO LSAB + and diaminobenzadine (DAB) as the chromogen. Serial sections of deparaffinized TMA sections were labelled with rabbit antihuman EZH2 anti body (Clone ZMD.309, 187395, 1:200, Life Technologies), rabbit antiDNMT1 (Clone H300, sc20701, 1:50, Santa Cruz Biotechnology), and mouse antihuman CD8 antibody (DAKO, M7103). Cores from several normal organ tissues were used as tissue controls on each slide.
The cores were quantified and analysed for the expression of EZH2 and DNMT1 with an Aperio imaging system (Genetix) and for the numbers of intratumoral CD8 + T cells in 0.1 mm 2 tumour. The specimens were digitalized with an auto mated platform (Aperio Technologies) and ScanScope XT and Spectrum Plus using TMA software version 9.1 scanning system. Cores were scored in high resolution at 40× . Tissue sections were scored manually on a computer screen, and a mean score for duplicate cores from each individual was calculated. Any discrepancies were resolved by subsequent consultation with diagnostic pathologists. Epigenetic marks, EZH2 and DNMT1 were localized in the nuclei, and were scored using the Hscore method 11, 32 . The tissues were divided into high and low epigenetic mark expression based on the median value of the expression level per core. The Hscore is a method of assessing the extent of nuclear immunoreactivity. The Hscore takes into account the percentage of positive cells (0-100%) in each inten sity category (0-3+) and computes a final score, on a continuous scale between 0 and 300. The score is obtained by the formula: 3 × percentage of strongly stain ing nuclei + 2 × percentage of moderately staining nuclei + percentage of weakly staining nuclei; giving a range of 0 to 300 11 . Staining with isotype antibody was used as negative control. In vivo tumour progression and immunotherapy models. ID8 mouse ovarian cancer cells have been described previously 34 . ID8 cells (5 × 10 5 ) were injected into peritoneal cavity of NSG mice or C57BL/6 mice (6-8 weeks old, Jackson Lab) 11, 32 . Tumour progression was monitored 2-3 times per week by Xenogen IVIS Spectrum in vivo bioluminescence imaging system (PerkinElmer). Tumour volume was calculated based on the total flux (photons per second). Tumour bearing mice were treated (i.p.) with 5 mg kg −1 DZNep (SML0305, Sigma), 50 mg kg −1 EPZ6438 (E7438, Active Biochem), 0.2 mg kg −1 5AZAdC (A3656, Sigma), or 10 mg kg −1 antiPDL1 (B7H1, clone 10F.9G2, BE0101, Bio X Cell) three times per week for two weeks. In some cases, tumour was dissected for the analysis of chemokine production or Tcell infiltration as indicated.
In an adoptive Tcell therapeutic model, human TAAspecific CD8 + T cells were generated in vitro and primary human ovarian cancer cells were inoculated subcu taneously into the flanks of NSG mice 11, 32 . TAAspecific CD8 + T cells (7 × 10 6 ) were intravenously transfused into tumourbearing mice. DZNep (5 mg kg −1 ), GSK126 (30 mg kg −1 ), and 5AZAdC (0.2 mg kg −1 ) treatments were started before Tcell transfusion by intraperitoneal administration three times per week. In some cases, mice received CD8 + T cells which were preincubated with antiCXCR3 for 1 h before in vivo transfusion, followed by intraperitoneal administration of 500 μ g anti CXCR3 three times per week. Tumour growth was monitored and recorded. Tumour cells and tumour infiltrating immune cells were isolated and studied by FACS, real time PCR and/or immunohistochemistry. All animal protocols were approved by the University of Michigan Committee on Use and Care of Animals (UCUCA). Statistical analysis. Wilcoxon ranksum tests were used to compare two inde pendent groups, and for paired groups, Wilcoxon signed rank tests were used for the comparison. Correlation coefficients (Spearman correlation, denoted by ρ, for ordinal data and Pearson correlation, denoted by r, for continuous data), together with a P value (null hypothesis is that r/ρ is zero), were computed to measure the degree of association between biomarkers. logrank test was used to compare time to tumour initiation between two groups. Overall patient survival was defined as the time from date of diagnosis to diseaserelated death. Survival functions were estimated by Kaplan-Meier methods.
Cox's proportional hazards regression was performed to model survival as a function of EZH2, DNMT1 and CD8 + T cells. The data were analysed as continu ous or categorized values and classified as low and high based on the median values, or the combination of EZH2 and DNMT1 (classified as EZH2 high DNMT1 high and EZH2 low DNMT1 low ), after adjusting for age and stage. We assessed the adequacy of the Cox regression model. Graphical and numerical methods were described 35 . We used ROC analysis 20 to evaluate the predictive accuracy of the levels of EZH2 and DNMT1, and CD8 + T cells for 60month survival. All analyses were done using SAS 9.3 software. P < 0.05 considered as significant. No statistical methods were used to predetermine sample size. Sample size was determined on the basis of animal experimental trials and in consideration of previous publications on similar experiments to allow for confident statistical analyses. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment unless state differently. shRNA. Primary ovarian cancer cells were stably transduced with a lentiviral shRNA expressing vector (nontarget shRNA (Ctl) or EZH2 shRNA, shEZH2). The levels of EZH2 and H3K27me3 were detected by western blotting. j, k, Effects of EZH2 knockdown on IFNGR2 and HLA-b gene expression. Primary ovarian cancer cells were stably transduced with non target shRNA (Ctl) or EZH2 shRNA (shEZH2). IFNGR2 (j) and HLA-b (k) gene expression was quantified by realtime PCR. (mean ± s.e.m.; n = 4). l, m, Effect of DZNep on H3K27me3 occupancy at T H 1type chemokine promoters. H3K27me3 ChIP assay was performed in primary ovarian cancer cells treated with DZNep with or without IFNγ . H3K27me3 levels at the gene promoter of CXCL9 and CXCL10 were normalized to the input (mean ± s.e.m.; n = 5, * P < 0.05, Wilcoxon test). n, Effects of EZH2 knockdown on H3K27me3 occupancy at the HoXb1 gene promoter. H3K27me3 ChIP assay was performed in shEZH2 or nontarget shRNA expressing primary ovarian cancer cells. H3K27me3 levels at the gene promoter of HoXb1 were normalized to the input (mean ± s.e.m.; n = 5, * P < 0.05, Wilcoxon test).
Extended Data Figure 5 | EZH2/H3K27 and DNMT1 interaction affects clinical outcome. a, b, Representative images of immunohistochemistry staining of EZH2 (a) and DNMT1 (b) in human ovarian cancer tissues. The levels of DNMT1 and EZH2 expression in the tumour were assessed by the Hscore method. c, d, The association between EZH2 (c), DNMT1 (d) and patient DFS in highgrade serous ovarian cancer. The high and low levels of EZH2 and DNMT1 were determined by the median values (see Extended Data Table 1 ). e, Relative impact of EZH2, DNMT1 and CD8 on patient DFS in highgrade serous ovarian cancer. The timedependent receiver operating characteristic (ROC) curve analysis was applied to evaluate the predictive accuracy of each marker for DFS. AUC, the area under the ROC curve; t = 60 months. f, Impact of the two parameters (EZH2 and DNMT1) on patient DFS. The analysis was performed on patients with highgrade serous ovarian cancer. Multiple comparisons were performed with logrank tests. EZH2 low DNMT1 low group (n = 49) versus EZH2 high DNMT1 high (n = 55) P < 0.00001. g, Representative images of immunohistochemistry staining of CD8 in human ovarian cancer specimen. Intratumoural CD8 + T cells were shown with antiCD8 + staining. The numbers of intratumoural CD8 + T cells were quantified in highpower fields (40×) (see Methods and Extended Data Table 1 ). h, The relationship between intratumoural CD8 + T cells and patient DFS in highgrade serous ovarian cancer (see Methods and Extended Data Table 1 ). i, Schematic diagram depicting the relationship among epigenetic T H 1type chemokine silencing, effector Tcell trafficking, and tumour immunity, immunotherapy and patient outcome. M, methylation.
